Lipopeptide and Poly I:C Synergistic Adjuvant for Vaccine Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, such as aluminum hydroxide, often fail to induce a strong and balanced immune response, particularly in terms of Th1 cell response and antibody isotypes like IgG2a and IgG2b, which are crucial for effective viral and cancer immunization, and require empirical development rather than rational prediction.
Innovation Solution
A vaccine composition comprising a lipopeptide selected from Pam3Cys-SKKKK and Pam3Cys-SR8, combined with poly I:C, which acts as a synergistic adjuvant to enhance antigen-specific antibody production and induce a balanced immune response, including high ratios of IgG2a/IgG1 and IgG2b/IgG1, without the need for covalent linking to the antigen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants like aluminum hydroxide are used, then vaccine formulation is simple and manufacturing is easy, but immune response strength and balance (particularly Th1 response and IgG2a/IgG2b production) is insufficient
Solution Approach 1:
The patent combines two distinct adjuvant components (lipopeptide and poly I:C) into a single vaccine formulation. The lipopeptide component targets Th1 response induction while poly I:C enhances overall immunogenicity, creating a synergistic effect that produces both strong and balanced immune responses including elevated IgG2a and IgG2b levels
Solution Approach 2:
The adjuvant system uses a composite formulation comprising lipopeptide (such as Pam3Cys-SKKKK or Pam3Cys-SR8) combined with poly I:C. This composite approach leverages the complementary mechanisms of both components to achieve reliable Th1-type immune responses and balanced antibody isotype production that conventional single-component adjuvants cannot achieve
2Reliability
If protein antigen alone is used, then vaccine composition is simple, but immune response magnitude and desired type (Th1 response) is not induced
Solution Approach 1:
The lipopeptide and poly I:C act as intermediary substances that bridge the gap between protein antigen administration and Th1 immune response induction. These adjuvant components provide the necessary costimulatory signals and cytokine induction (particularly IFN-γ and IL-12) that convert a simple protein antigen formulation into one that reliably induces Th1-type immunity
3Reliability
If natural adjuvant functions from whole microorganisms are used, then epitope and adjuvant function are provided together, but immune response strength and quality is often not strong enough
Solution Approach 1:
The patent extracts and isolates the essential adjuvant functions from whole microorganisms into discrete, purified components (lipopeptide and poly I:C). This extraction allows for precise control over immune response induction without the complexity and variability of using whole pathogen preparations, while achieving stronger and more reliable immune responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of Pam3Cys-SKKKK and poly I:C significantly increases antigen-specific antibody production and induces a potent Th1 immune response, outperforming conventional adjuvants by promoting the production of IgG2a and IgG2b antibodies, effectively enhancing immunogenicity and vaccine efficacy against viral and parasitic infections and cancer.
Implementation Method 1
An adjuvant plays a role in promoting immune response by accelerating or amplifying one or more specific phases of various immune response inducing processes
Implementation Method 2
a powerful vaccine composition comprising a lipopeptide selected from the group consisting of Pam3Cys-SKKKK and Pam3Cys-SR8; and poly I:C
Data Source
Figure 1~2
Figure 3a~3c
Figure 4
AI summary
The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant comprising a lipopeptide and poly I:C of the present invention is used, the level of antigen specific antibody induction is synergistically increased and ThI type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral infection and cancer.